# Vitamin K Bone Density Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/vitamin-k-bone-density-randomized-trial-evidence-review
Category: evidence-review
Summary: Vitamin K Bone Density Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are
Last reviewed: 2026-05-22
Reviewed by: Migaku Evidence Review
# Vitamin K Bone Density Randomized Trial: What the Evidence Says

## Quick Answer

Vitamin K Bone Density Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 randomized trial, 1 narrative review.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Effects of Eggshell Calcium- and Vitamin D-Fortified HMR Combined with Aerobic Exercise on Bone Mineral Density in Postmenopausal Women: A Pilot Randomized Controlled Trial | randomized trial | 2 | 2026-02-12 | 10.3390/nu18040605 |
| Revisiting Intranasal Salmon Calcitonin: Historical Osteoporosis Evidence and a Potential Role in Acute Orthopaedic Pain Management | narrative review | 3 | 2026-04-01 | 10.2106/JBJS.RVW.26.00021 |

## What The Sources Report

- Bone health is a major concern for postmenopausal women, as estrogen deficiency after menopause accelerates bone resorption and suppresses bone formation, leading to reduced bone mineral density (BMD) and an increased risk of fractures. [Jung Susie (2026); evidence level 2]
- Among the various risk factors for osteoporosis, modifiable lifestyle factors-particularly insufficient calcium and vitamin D intake, as well as inadequate physical activity-are of special importance, alongside other established factors such as advanced age and low body mass index (BMI). [Jung Susie (2026); evidence level 2]
- Accordingly, contemporary guidelines no longer recommend IN-CAL as first-line treatment for chronic osteoporosis, and concerns regarding a potential malignancy signal further limited long-term use. [Ahmad Areeb (2026); evidence level 3]
- A landmark review by Plosker and McTavish summarized the pharmacologic and clinical evidence for IN-CAL through the mid-1990s. [Ahmad Areeb (2026); evidence level 3]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For vitamin K bone density randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Jung Susie (2026). Effects of Eggshell Calcium- and Vitamin D-Fortified HMR Combined with Aerobic Exercise on Bone Mineral Density in Postmenopausal Women: A Pilot Randomized Controlled Trial. DOI: 10.3390/nu18040605. PMCID: PMC12942995. PMID: 41754122. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12942995/
- Ahmad Areeb (2026). Revisiting Intranasal Salmon Calcitonin: Historical Osteoporosis Evidence and a Potential Role in Acute Orthopaedic Pain Management. DOI: 10.2106/JBJS.RVW.26.00021. PMCID: PMC13048325. PMID: 41945663. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ Creative Commons Attribution-Non Commercial-No Derivatives License.... https://pmc.ncbi.nlm.nih.gov/articles/PMC13048325/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.